Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Common Equity: 2023-2024

  • Zhengye Biotechnology Holding's Common Equity rose 2.51% to $48.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.3 million, marking a year-over-year increase of 2.51%. This contributed to the annual value of $48.3 million for FY2024, which is 0.61% up from last year.
  • According to the latest figures from Q4 2024, Zhengye Biotechnology Holding's Common Equity is $48.3 million, which was up 2.51% from $47.1 million recorded in Q4 2023.
  • Zhengye Biotechnology Holding's Common Equity's 5-year high stood at $48.3 million during Q4 2024, with a 5-year trough of $47.1 million in Q4 2023.
  • In the last 2 years, Zhengye Biotechnology Holding's Common Equity had a median value of $47.7 million in 2023 and averaged $47.7 million.
  • Data for Zhengye Biotechnology Holding's Common Equity shows a peak YoY rose of 2.51% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Zhengye Biotechnology Holding's Common Equity stood at $47.1 million in 2023, then rose by 2.51% to $48.3 million in 2024.